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Abstract S100A4 (metastasin 1) belongs to the S100
family of Ca2+ binding proteins. While not present in most
diVerentiated adult tissues, S100A4 is upregulated in the
micromilieu of tumors. It is primarily expressed by tumor-
associated macrophages, Wbroblasts, and tumor endothelial
cells. Due to its strong induction in tumors S100A4 is a
promising target for cancer immunotherapy. By reverse
immunology, using epitope prediction programs, we identi-
Wed 3 HLA-A1-restricted peptide epitopes (S100A4 A1-1,
A1-2, and A1-3) which are subject to human T cell
responses as detected in peripheral blood of melanoma
patients by means of IFN- ELISPOT and cytotoxicity
assays. In addition, IFN- responses to S100A4 A1-2 can
not only be induced by stimulation of T cells with peptide-
loaded DC but also by stimulation with S100A4 protein-
loaded DC, indicating that this epitope is indeed generated
by processing of the endogenously expressed protein. In
addition, S100A4 A1-2 reactive T cells demonstrate lysis
of HLA-A1+ Wbroblasts in comparison to HLA-A1¡ Wbro-
blasts. In summary, this HLA-A1-restricted peptide epitope
is a candidate for immunotherapeutical approaches target-
ing S100A4-expressing cells in the tumor stroma.
Keywords CTL · HLA-A1 epitope · Melanoma · 
Metastasin 1 · S100A4 · Tumor stroma
Introduction
S100A4, also referred to as metastasin 1 (mts1), Wbroblast-
speciWc protein 1 (FSP1), placental calcium-binding pro-
tein, CAPL, calvasculin, p9Ka, pEL-98, 18A2, or 42A
belongs to the family of EF-hand calcium-binding proteins.
S100A4 has both intracellular and extracellular functions.
By binding to diVerent target molecules S100A4 inXuences
cell motility, invasion, adhesion, proliferation, apoptosis,
remodeling of the extracellular matrix, and angiogenesis
[15, 41]. S100A4 expression is enhanced under several
pathological conditions including cancer, where it might be
expressed in and released from tumor cells, tumor stroma
cells or both [8, 48, 49]. Indeed, S100A4 expression was
demonstrated in many cell types participating in formation
of the tumor stroma, e.g., cancer-associated Wbroblasts,
tumor endothelial cells, and tumor-associated macro-
phages. Notably, an extensive study in breast cancer
describes preferential expression of S100A4 in macro-
phages and Wbroblasts [8]. All these stroma cells contribute
to the development and progression of cancer by secretion
of growth and angiogenic factors or extracellular matrix
degrading enzymes leading to enhanced tumor cell prolifer-
ation, invasion, angiogenesis, and Wnally metastasis and in
consequence are potential anti-cancer therapeutical targets
[20, 21, 31]. S100A4 itself has been implicated in disease
development and progression, as it promotes the oncogenic
phenotype of tumor cells. Its expression has been described
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[12, 22, 30, 37, 46, 54], ovary [25], thyroid [23, 36, 57],
esophagus [38], bladder [1, 11], gallbladder [9], colon [53],
colorectum [10, 19], pancreas [2, 40, 45] and prostate [17],
gastric cancers [14, 26, 55], lung [27, 34], and brain cancers
[44, 52]. S100A4 expression has also been described in
primary and metastatic melanoma [3, 32, 39]. Elevated
S100A4 levels are associated with a more aggressive phe-
notype and a poor prognosis [11, 18, 26, 36]. Due to its
involvement in disease development and progression and
its broad expression in the tumor microenvironment,
S100A appears as an attractive target for cancer therapy
that should allow the destruction of the tumor directly by
targeting the cancer cells themselves and indirectly by
destroying the supporting tumor stroma cells. Indeed, the
destruction of the tumor stroma may be essential to eradi-
cate tumors [56].
Up to date, approaches for down-regulation of S100A4
expression by ribozymes [33] or RNA interference [51, 52]
have demonstrated the feasibility of S100A4-directed anti-
tumor therapies. For example, the reduction of its expres-
sion in a murine model of thyroid carcinoma was accompa-
nied by enhanced sensitivity to chemotherapy [51]. To
analyse if S100A4 may be a therapeutic target for cancer
immunotherapy, we applied reverse immunology to iden-
tify S100A4-derived T cell epitopes and demonstrated their
immunogenicity ex vivo as well as the occurrence of spon-
taneous immune responses against these in melanoma
patients.
Materials and methods
Cells and cell lines
The HLA-A1+ lymphoblastoid cell line BM36.1 and the
melanoma cell lines MelJuso, Mel2a, and Mel888 were cul-
tured in RPMI 1640/10% FCS supplemented with 100 U
penicillin/ml and 100 g streptomycin/ml.
Human skin Wbroblasts were isolated by incubation of
normal skin tissue pieces obtained from the margins after
resection of nevi or cancerous lesions in 0.25% collagenase
(Collagenase D, Boehringer Mannheim, Mannheim, Ger-
many) and 0.1 mg/ml DNAse. The resulting suspension
was Wltered through a Wne mesh. Obtained cells were main-
tained in RPMI 1640 supplemented with 10% FCS.
After informed consent PBL were collected from HLA-
A1+ patients (n = 16) with advanced malignant melanoma.
PBL were isolated using Lymphoprep separation (Axis-
Shield PoC AS, Oslo, Norway) according to the manufac-
turer’s instructions and used directly or after cryopreservation.
PBL were cultured in RPMI 1640/10% human AB serum.
CD8+ T cells were negatively selected using the CD8+ T
Cell Isolation Kit II (Miltenyi Biotec GmbH, Bergisch
Gladbach, Germany) according to the manufacturer’s rec-
ommendations.
Dendritic cells were generated from PBL by adherence
on culture dishes at 37°C for 60 min in RPMI 1640
enriched with 10% human AB serum. Adherent monocytes
were cultured in RPMI 1640 supplemented with 10%
human AB serum in the presence of IL-4 (1,000 U/ml) and
GM-CSF (800 U/ml) for 6 days. DCs were matured by
addition of IL1 (2 ng/ml), IL-6 (1,000 U/ml), TNF
(10 ng/ml), and PGE2 (1 g/ml). The next day the resulting
mature DC were pulsed with 10 M peptide and 3 g 2-
microglobulin/ml overnight at 37°C. For loading of DC
with S100A4 protein 1 £ 106 immature DC/ml were incu-
bated with 50 g protein/ml overnight before adding the
maturing cocktail.
Immunohistochemical staining
After pre-treatment with 0.1% pronase (Roche Diagnostics
GmbH, Mannheim, Germany) for 20 min at 37°C and pro-
teinase K (Dako, Hamburg, Germany) for 10 min at room
temperature, respectively, paraYn sections of normal skin,
nevi, and melanoma were stained with S100A4-speciWc
rabbit antiserum or anti CD68 clone PG-M1 (Dako) and the
appropriate DakoCytomation Envison+ Systems (Dako)
followed by the Vector Nova red system (Vector Laborato-
ries, Burlingame, USA) according to the manufacturer’s
instructions. As negative control sections were stained with
normal rabbit antiserum or without primary antibody,
respectively.
S100A4 nonamer peptides
HLA-A1-restricted nonamer peptides derived from the full-
length human S100A4 protein were selected using both
SYFPEITHI [43] and BIMAS [42] peptide binding algo-
rithms freely available via the internet (http://www.syfpei-
thi.de/ and http://bimas.cit.nih.gov/molbio/hla_bind/). The
peptides were synthesized by GenScript Corporation (Pis-
cataway, New Jersey, USA). HLA-A1-restricted peptides
derived from inXuenza nucleoprotein (NP) peptide 44–52
(CTELKLSDY) [13] were used as controls.
ELISPOT assays
The human IFN- ELISPOT assay was used to quantify
peptide epitope-speciWc IFN--releasing eVector cells as
described previously [5]. BrieXy, nitrocellulose-bottomed
96-well plates (MultiScreen MAIP N45, Millipore GmbH,
Schwalbach, Germany) were activated with 35% ethanol,
washed with PBS, and coated with anti-IFN- Ab (1-D1K,
Mabtech, Hamburg, Germany). The wells were washed and123
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viers, Belgium) before adding 1 £ 104 stimulator BM36.1
cells loaded with or without 10 M peptide and 3 £ 105,
1 £ 105, or 3 £ 104 eVector cells. To minimize background
in samples stimulated with DC preincubated with S100A4
protein or peptides, only 1 £ 105, 3 £ 104, and 1 £ 104
eVector cells were used. After incubation overnight the
wells were washed with PBS followed by addition of bio-
tinylated secondary Ab (7-B6-1-Biotin, Mabtech, diluted in
PBS/1% BSA). The plates were incubated for 2 h, washed,
and streptavidin-enzyme conjugate (Streptavidin-ALP-PQ,
Mabtech, diluted in PBS/1% BSA) was added. Incubation
at room temperature for 1 h was followed by washing with
wash buVer and substrate buVer (0.1 M NaCl, 50 mM
MgCl2, 0.1 M Tris–HCl, pH 9.5), and addition of enzyme
substrate NBT/BCIP (Mabtech). The reaction was stopped
by washing with tap water upon the appearance of dark pur-
ple spots. Spots were counted using the ImmunoSpot Series
2.0 Analyzer (CTL Cellular Technology Ltd., Schwäbisch
Gmünd, Germany). The peptide-speciWc CTL frequency
was calculated from the numbers of spot-forming cells. All
assays were performed at least in duplicates. To extend the
sensitivity of the ELISPOT assay, PBL were stimulated
once in vitro before analysis. At day 0, PBL were plated in
a cell concentration of 1 £ 106/ml in 6-well plates (Greiner
GmbH, Frickenhausen, Germany) in X-vivo medium
(Cambrex) supplemented with 10% heat inactivated human
AB serum in the presence of 10 M peptide (GeneScript
Corporation). Alternatively, 1 £ 105 irradiated (50 Gy)
DC/ml loaded with S100A4 protein or peptide were used
for stimulation of 1 £ 106 PBL/ml in the presence of 40 U
IL-2/ml (Proleukin, Chiron GmbH, Munich, Germany). IL-
2 was added every 3–4 days to the culture. The cultured
cells were tested for reactivity in ELISPOT on day 7.
Cytotoxicity assay
For the microcytotoxicity assay, 2 £ 102 target cells/well
were plated in Terasaki plates (Nunc, Wiesbaden, Ger-
many) for 24 h. After 24 h, the in vitro prestimulated lym-
phocytes were added at eVector:target ratios of 30:1 and
10:1 in a Wnal volume of 10 l [7]. After overnight incu-
bation, the plates were washed, Wxed with ¡20°C cold
methanol, and stained with Giemsa-Solution (Merck,
Darmstadt, Germany). All stained target cells were
counted and the percent of lysis was calculated. As nega-
tive control target cells only, without adding eVector cells,
were used. In addition, speciWc lysis of Wbroblasts or
Mel2a was analysed in a 4 hour standard chromium
release assay. Mel2a targets were preincubated with or
without 10 M peptide, 20 g/ml W6/32 antibody (Dako,
Hamburg, Germany), or IgG2a isotype control antibody
(Dianova, Hamburg, Germany). Cold targets were prein-
cubated with 10 M S100A4 A1-2 or irrelevant peptide
derived from inXuenza NP 44–52.
Sequence similarity search
A search for proteins containing the identiWed S100A4
peptides was done using the protein blast tool available at
http://www.ncbi.nlm.nih.gov.
Statistical analysis
Statistical analysis was performed using GraphPad Prism
version 4.03 for Windows (GraphPad Software, San Diego
California USA, www.graphpad.com).
Results
S100A4 is upregulated in the tumor micromilieu
S100A4 upregulation in tumor and stroma cells has been
demonstrated previously in a variety of cancers. Accord-
ingly, immunohistochemical staining of normal skin and
melanoma demonstrates that in situ expression of S100A4
in normal skin is absent or restricted to macrophages
(Fig. 1a, e). Although in melanoma the extend of expres-
sion varied between patients (Fig. 1b, c), in addition to
macrophages, cancer-associated Wbroblasts, tumor endothe-
lial cells, and melanoma cells themselves are S100A4+
(Fig. 1). No positive cells were detected in control stainings
with normal rabbit serum. Notably, we also detected
S100A4 protein expression in benign nevi (data not
shown).
Spontaneous IFN- responses to HLA-A1-restricted 
S100A4-derived peptide epitopes
The complete amino acid sequence of the human S100A4
protein consisting of 101 amino acids was searched for
putative HLA class I binding peptides using the epitope
prediction programs BIMAS [42] and SYFPEITHI [43].
Epitopes with SYFPEITHI scores >20 were found for
HLA-A1, -A3, and -B8, whereas no high aYnity peptides
restricted to the HLA class I antigens HLA-A2, -B7, or
-B27 were predicted. The highest score was reached for the
HLA-A1-restricted peptides. Thus, we focussed on HLA-
A1-restricted S100A4 epitopes in the further studies. In
addition, the HLA-A1 allele is frequently expressed in the
Caucasian population (www.allelefrequencies.net) [35]. To
this end, three HLA-A1-restricted nonamer peptides
(S100A4 A1-1, S100A4 A1-2, and S100A4 A1-3) with
scores >20 for SYFPEITHI were synthesized (Table 1,
Fig. 2a). We tested for spontaneous CTL responses to these123
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from HLA-A1+ melanoma patients by IFN- ELISPOT.
This analysis revealed, that in several patients IFN-
responses to the three HLA-A1-restricted peptides were
indeed detected (Fig. 2b, c).
Peptide- versus protein-induced T cell responses
To further evaluate the immunogenicity of both S100A4
and the S100A4-derived peptides, we stimulated lympho-
cytes from HLA-A1+ donors in vitro with DC which where
either given the possibility to process the whole protein or
pulsed with the peptides. The response was measured by
IFN- release ELISPOT assay to either protein or peptides.
This analysis revealed that, in contrast to the epitopes
S100A4 A1-1 and A1-3, IFN- responses to the peptide
S100A4 A1-2 were not only induced by the respective pep-
tides but also after in vitro stimulation using DC which pro-
cessed the whole protein (Fig. 2d). The lack of IFN-
response to the S100A4 A1-1 and A1-3 peptides after stim-
ulation with S100A4 protein-loaded DC indicates that in
this case no unspeciWc or CD4+ T cell responses were
induced. This indicates that only the S100A4 A1-2 epitope
is cross-presented and indeed generated by natural process-
ing of the antigen, whereas the epitopes A1-1 and A1-3
albeit binding to HLA-A1 are not. Furthermore, after pres-
timulation with DC which processed S100A4 protein the
IFN- release response to the complete S100A4 protein was
signiWcantly higher than in the response to the S100A4 A1-2
peptide indicating that other epitopes than the S100A4 A1-2
contribute to the anti S100A4 immune reaction (Fig. 2e).
Although the majority of the additional immune response
can likely be attributed to CD4+ T cells, it is also feasible
that other MHC class I epitopes are cross-presented.
Cytotoxic activity of S100A4-speciWc T cells
The lytic capacity of S100A4-reactive CTL was tested in
cytotoxicity assays. To this end, lymphocytes were stimu-
lated with DC pulsed with S100A4 peptides A1-2, A1-3, or
inXuenza NP peptide. Subsequently, lysis of peptide-loaded
HLA-A1+ melanoma cell line MelJuso was evaluated
(Fig. 3a). Notably, the target cells were either used directly
or after pulse with the indicated peptides. All peptide-
loaded target cells were similarly lysed by the activated
lymphocytes. However, only lymphocytes stimulated with
the naturally processed S100A4 peptide, i.e., S100A4 A1-2,
were able to lyse the S100A4+ target cell without the addi-
tional peptide pulse; thus, conWrming the earlier observation
that only the S100 A4 A1-2 peptide epitope is suitable for
S100A4 targeted immunotherapy. In order to test if S100A4
peptide-induced CTL would also recognize cancer-associ-
ated Wbroblasts, we performed cytotoxicity assays against in
vitro stimulated Wbroblasts expressing S100A4. ConWrming
the prior analyses S100A4 A1-2 stimulated PBL lysed
Wbroblast much more eVectively than S100A4 A1-1 and
A1-3 stimulated PBL (Fig. 3b). Besides, lysis of HLA-A1+
Wbroblasts by S100A4 A1-2-stimulated PBL was clearly
Fig. 1 S100A4 expression in the skin. Sections of normal skin (a, e) and primary melanoma (b–d, f–h) were stained with anti-S100A4 antiserum
(a–c, e–g) or anti CD68 (d, h). £10 (a–d) and £40 (e–h)
Table 1 Position, amino acid sequence, and peptide binding predic-
tion of HLA-A1-restricted S100A4 peptides
a The higher the score the higher the aYnity predicted
Name Position Sequence SYFPEITHI scorea
S100A4 A1-1 11–19 VMVSTFHKY 21
S100A4 A1-2 31–39 KSELKELLT 22
S100A4 A1-3 67–75 DNEVDFQEY 28123
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verify that lysis of S100A4+ target cells, e.g., Mel2a, is
mediated at least in part by CD8+ T cells, a CD8+ enriched
eVector cell population was used. In blocking experiments
lysis of target cells was reduced in the presence of the anti
HLA-class I antibody W6/32 (Fig. 3c). In contrast, addition
of isotype control antibody did not reduce target cell lysis
(not shown). This Inhibition of lysis by blocking of MHC
class I/TCR interaction demonstrated the MHC class I
dependent cytotoxic activity (Fig. 3c). Furthermore, cold
target inhibition experiments revealed that the T cells lysing
the S100A4 expressing melanoma cells are the same that
recognize the peptide-loaded target cells. Coincubation with
the HLA-A1+, S100A4¡ cell line Mel888 loaded with
S100A4 A1-2 signiWcantly reduced lysis of hot targets by
S100A4 1-2 stimulated CD8+ cells; in contrast, coincuba-
tion with cold targets loaded with the irrelevant inXuenza
NP peptide 44-52 did not impair speciWc lysis (Fig. 3d).
Fig. 2 HLA-A1-restricted S100A4 peptides and S100A4-directed
IFN- immune responses. a In the amino acid sequence of the S100A4
protein the HLA-A1-restricted peptides S100A4 A1-1 (amino acid
position 11–19: VMVSTFHKY), A1-2 (amino acid position 31–39:
KSELKELLT), and A1-3 (amino acid position 67–75: DNEVDFQEY)
were selected using epitope prediction programs. b IFN- ELISPOT
responses of PBL of melanoma patients to S100A4 peptides A1-1, A1-2,
and A1-3 after in vitro stimulation with S100A4 peptides are depicted
as speciWc spots/105 cells = [mean spots+peptide ¡ mean spots¡peptide].
c Representative results of IFN- ELISPOTs are depicted as speciWc
spots/3 £ 105 cells (black columns), 1 £ 105 cells (dark gray col-
umns), and 3 £ 104 cells (light gray columns). d 1 £ 104 PBL of a mel-
anoma patient prestimulated with DC loaded with S100A4 peptides
A1-1, A1-2, or A1-3 (black columns) or with S100A4 protein (gray
columns) were tested for their reactivity to S100A4 peptide-loaded DC
in IFN- ELISPOT. e 1 £ 105 (black columns) and 3 £ 104 (gray col-
umns) PBL of a melanoma patient were prestimulated with empty DC,
DC incubated with S100A4 protein or DC loaded with the S100A4 A1-
2 epitope. The IFN- response to the S100A4 protein and A1-2 epitope
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To estimate the risk of S100A4 peptide-directed therapies,
the amino acid sequences of S100A4 family members were
searched for the S100A4 A1-1, A1-2, and A1-3 epitopes
and Blast searches were done for each of the identiWed
S100A4 peptides. Apart from S100A4, no identical hit
appeared for S100A4 A1-1 and only one other exact match,
i.e., leukemia multidrug resistance associated protein,
turned up for S100A4 A1-2 and A1-3 (Fig. 4).
Discussion
Melanoma is an immunogenic tumor, known to induce
spontaneous immune responses which may result in partial
regressions of primary tumors. This observation has led to
the development of several immune therapeutic approaches
including tumor speciWc vaccination. We have selected
S100A4 as immunological target molecule and veriWed its
upregulation in the tumor micromilieu of melanoma
(Fig. 1). In addition, a correlation between S100A4 protein
expression in melanoma and aggressive phenotype, espe-
cially in early superWcial spreading melanomas, has been
described [3]. Notably, in the presented report we charac-
terized a HLA-A1-restricted peptide epitope, S100A4 A1-
2, that is generated by processing of the complete S100A4
protein, demonstrated by reactivity to S100A4 protein-
loaded DC, HLA-A1+ Wbroblasts, and HLA-A1+ melanoma
cells (Figs. 2 and 3). Interestingly, two other HLA-A1-
restricted peptide epitopes were predicted by the used com-
puter algorithms and ex vivo immune responses to these
epitopes were detected in peripheral blood of melanoma
Fig. 3 S100A4 directed cytotoxic activity of PBL of melanoma pa-
tients. All eVector cells were obtained from melanoma patients. a PBL
were stimulated with DC incubated with S100A4 peptides A1-2, A1-3
or control peptide derived from inXuenza NP. Lysis of peptide pulsed
cells of the HLA-A1+ melanoma cell line MelJuso was analysed by
cytotoxicity assays in eVector to target ratios of 30:1 (black columns),
and 10:1 (gray columns). b S100A4 A1-1, A1-2 or A1-3 peptide
incubated DC were used to stimulate PBL. Lysis of HLA-A1+ and
HLA-A1¡ Wbroblasts was tested in cytotoxicity assays in eVector to
target ratios of 30:1. c CD8+ T cell enriched PBL were stimulated with
DC loaded or not with S100A4 A1-2 peptide. Lysis of the HLA-A1+/
S100A4+ melanoma cell line Mel2a, preincubated or not with W6/32,
was analysed by cytotoxicity assay in eVector to target ratios of 5:1
(black columns) and 2.5:1 (gray columns). d Lysis of Mel2a target cells
by CD8+ T cells stimulated with S100A4 A1-2 peptide-loaded DC was
analysed in an eVector to target ratio of 10:1 in a cold target inhibition
assay. The S100A4-, HLA-A1+ Mel888 cell line was incubated with
the S100A4 1-2 epitope or an irrelevant control peptide and added as
cold target in hot:cold ratios indicated
a
prestimulation
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lated with DC which processed the whole recombinant
S100A4 protein only responses to one peptide, S100A4
A1-2, were induced. Vice versa only S100A4 A1-2 reactive
T cells released IFN- in response to S100A4 processing
DC or killed target cells without these being pulsed with
peptide. This observation illustrates the limitations of
reverse immunology and conWrms the need for conWrma-
tion assays demonstrating the presentation of identiWed epi-
topes by the desired target cells, e.g., S100A4 A1-2 on
Wbroblasts or melanoma cells.
The presented results suggest that T cell responses to
S100A4 A1-2 can be induced by vaccination, e.g., allow-
ing the development of an immune therapy with a low risk
of inducing immune escape variants since S100A4 is
expressed both in melanoma cells as well as in the geneti-
cally relatively stable tumor stroma cells, which promote
tumor progression. However, it has to be noted that
S100A4 expression is not completely restricted to tumor
cells and tumor stroma cells. Although S100A4 expression
has not been detected in most normal tissues, e.g., obtained
from the breast, colon, thyroid, kidney, and pancreas, its
expression has been described for lymphoid organs and
white matter astrocytes [16, 28]. Moreover, S100A4 is
upregulated in injured tissues [4, 6, 29, 50]. Another con-
cern regarding side eVects is cross targeting of other S100
family members. The S100 proteins are widely expressed
and fulWll diverse functions [47]. The amino acid identity
of S100A4 and other S100 proteins is up to 61%
(S100A2). However, Blast search for the S100A4 A1-2
peptide resulted in one other identical hit apart from
S100A4 only, i.e., leukemia multidrug resistance associ-
ated protein (Fig. 4). Leukemia multidrug resistance asso-
ciated protein has once been described so far, in the
leukemia cell line HL60 [24]. Although predictable side
eVects using S100A4 A1-2 due to cross reaction with other
S100A4 family members are low, possible adverse side
eVects of S100A4 targeting therapies have to be addressed
in future studies.
In summary, S100A4 is an attractive target for anti-can-
cer therapy as its expression is elevated in the tumor
micromilieu, both in tumor and tumor stroma cells. Hence,
it is possible to develop strategies to simultaneously target
diVerent cell types contributing to tumor progression. The
identiWcation of an HLA-A1-restricted peptide derived
from S100A4 will allow to investigate if active immunisa-
tion to S100A4+ cells is an feasible option for anti-cancer
immunotherapy.
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